Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executive
NASDAQ:SGMT